.15 semaglutide Injections Kirkland & Bellevue γ-Glu(15)-Semaglutide | CS-O-59700 | Clearsynth

For patients medically qualified to enroll in the IVIM program, the following aspects of medical weight loss therapy are discussed with their medical provider during their first medical consultation: - Medical history documented within their intake form - Past attempts at non-medical weight loss - Past attempts using medical weight loss -Available GLP-1 therapies oEvidence based assessment of anticipated medical weight loss results oDiscussion regarding potential side effects and rates of occurrence oDiscussion regarding potential adverse events and rates of occurrence oSocioeconomic variables regarding cost of therapy This includes an insurance assessment for potential coverage Benefits verification and prior authorization submission for patients eligible for GLP-1 coverage through their insurer -Lifestyle elements focused on throughout the IVIM program oNutritional elements: Minimal focus on calorie counts and caloric restriction Heavy focus on macronutrient profiles High protein dietary preference High fiber dietary preference Minimizing simple sugars Dense macronutrient foods to counterbalance reduced dietary intake while on GLP-1 therapy Hydration goals based on gender and body weight Supplement optimization based on individual dietary preferences oExercise elements: A core focus on enhancing overall activity and increasing over time based on the patient's baseline Recommendation for combination of both cardiovascular exercise and strength training with focus on enjoyable, convenient activity to maximize adherence No stringent or defined requirement for exercise activity oSleep and mental health Raising awareness on the impact of sleep and stress levels as it relates to weight maintenance optimization -Utilization of the technology platform to enhance results oMobile application downloads with brief training and teaching on utilization of the mobile app for tracking, nutritional advice, and access to the IVIM care team oEncouragement for patient tracking of weight loss and lifestyle components for enhanced coaching oEasy access point for scheduling appointments and communicating with the medical care team -Utilization of the community for emotional support and enhanced accountability oEnrollment into the IVIM community oEmotional support features and identification of common groups (PCOS, diabetes, hypothyroidism, etc.) - What to expect while on the IVIM program - Selection of medical therapy and dosing - Dosing and administration instructions - Guidance on injectable therapies Active monitoring on the IVIM protocol: All patients enrolled in the IVIM protocol received access to active monitoring throughout the duration of the program

The most common adverse effects of weight loss injections include nausea, vomiting, diarrhea, constipation, and abdominal discomfort

With repeated dosing, these ratios actually fall to about 0.160.21 for Cmax,ss and 0.150.18 for AUC,ss

These effects are typically temporary and tend to improve as the body adjusts to the medication

Glycemic Control in Type 2 Diabetes In people with type 2 diabetes , retatrutide has produced HbA1c reductions close to 2 percentage points in trials, a magnitude often associated with multi-drug regimens

Compounded medications are produced in regulated facilities and compounding pharmacies are licensed and inspected by State Boards of Pharmacy